Evan S Dellon1, Spencer Rusin2, Jessica H Gebhart3, Shannon Covey2, Leana L Higgins3, RoseMary Beitia3, Olga Speck2, Kimberly Woodward2, John T Woosley2, Nicholas J Shaheen1. 1. 1] Center for Esophageal Diseases and Swallowing, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA [2] Center for Gastrointestinal Biology and Disease, Division of Gastroenterology and Hepatology, Department of Medicine, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA. 2. Department of Pathology and Laboratory Medicine, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA. 3. Center for Esophageal Diseases and Swallowing, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA.
Abstract
OBJECTIVES: Noninvasive biomarkers would be valuable for diagnosis and monitoring of eosinophilic esophagitis (EoE). The aim of this study was to determine the utility of a panel of serum biomarkers for the diagnosis and management of EoE. METHODS: We conducted a prospective cohort study of consecutive adults undergoing outpatient esophagogastroduodenoscopy. Incident cases of EoE were diagnosed per consensus guidelines; controls had gastroesophageal reflux disease (GERD) or dysphagia and did not meet the EoE criteria. EoE cases were treated with topical steroids and had repeat endoscopy. Pre- and post-treatment serum samples were analyzed in a blinded manner for interleukin (IL)-4, IL-5, IL-6, IL-9, IL-13, transforming growth factor (TGF)-α, TGF-β, tumor necrosis factor-α, eotaxin-1, -2, and -3, thymic stromal lymphopoietin (TSLP), major basic protein, and eosinophil-derived neurotoxin. Cases and controls were compared at baseline, and pre- and post-treatment assays were compared in cases. RESULTS: A total of 61 incident EoE cases and 87 controls were enrolled; 51 EoE cases had post-treatment serum analyzed. There were no significant differences in any of the biomarkers between EoE cases and controls at baseline. IL-13 and eotaxin-3 for cases and controls were 85 ± 160 vs. 43 ± 161 pg/ml (P=0.12) and 41 ± 159 vs. 21 ± 73 (P=0.30). There were no significant differences in assay values among cases before and after treatment. There were also no differences after stratification by atopic status or treatment response. CONCLUSIONS: A panel of inflammatory factors known to be associated with EoE pathogenesis were not increased in the serum, nor were they responsive to therapy. None of these biomarkers are likely candidates for a serum test for EoE. Histologic analysis for diagnosis and management of EoE continues to be necessary, and novel, less invasive, biomarkers are needed.
OBJECTIVES: Noninvasive biomarkers would be valuable for diagnosis and monitoring of eosinophilic esophagitis (EoE). The aim of this study was to determine the utility of a panel of serum biomarkers for the diagnosis and management of EoE. METHODS: We conducted a prospective cohort study of consecutive adults undergoing outpatient esophagogastroduodenoscopy. Incident cases of EoE were diagnosed per consensus guidelines; controls had gastroesophageal reflux disease (GERD) or dysphagia and did not meet the EoE criteria. EoE cases were treated with topical steroids and had repeat endoscopy. Pre- and post-treatment serum samples were analyzed in a blinded manner for interleukin (IL)-4, IL-5, IL-6, IL-9, IL-13, transforming growth factor (TGF)-α, TGF-β, tumor necrosis factor-α, eotaxin-1, -2, and -3, thymic stromal lymphopoietin (TSLP), major basic protein, and eosinophil-derived neurotoxin. Cases and controls were compared at baseline, and pre- and post-treatment assays were compared in cases. RESULTS: A total of 61 incident EoE cases and 87 controls were enrolled; 51 EoE cases had post-treatment serum analyzed. There were no significant differences in any of the biomarkers between EoE cases and controls at baseline. IL-13 and eotaxin-3 for cases and controls were 85 ± 160 vs. 43 ± 161 pg/ml (P=0.12) and 41 ± 159 vs. 21 ± 73 (P=0.30). There were no significant differences in assay values among cases before and after treatment. There were also no differences after stratification by atopic status or treatment response. CONCLUSIONS: A panel of inflammatory factors known to be associated with EoE pathogenesis were not increased in the serum, nor were they responsive to therapy. None of these biomarkers are likely candidates for a serum test for EoE. Histologic analysis for diagnosis and management of EoE continues to be necessary, and novel, less invasive, biomarkers are needed.
Authors: Evan S Dellon; Xiaoxin Chen; C Ryan Miller; John T Woosley; Nicholas J Shaheen Journal: Am J Gastroenterol Date: 2012-07-10 Impact factor: 10.864
Authors: Carine Blanchard; Emily M Stucke; Karen Burwinkel; Julie M Caldwell; Margaret H Collins; Annette Ahrens; Bridget K Buckmeier; Sean C Jameson; Allison Greenberg; Ajay Kaul; James P Franciosi; Jonathan P Kushner; Lisa J Martin; Philip E Putnam; J Pablo Abonia; Suzanne I Wells; Marc E Rothenberg Journal: J Immunol Date: 2010-03-05 Impact factor: 5.422
Authors: Carine Blanchard; Emily M Stucke; Beatriz Rodriguez-Jimenez; Karen Burwinkel; Margaret H Collins; Annette Ahrens; Eileen S Alexander; Bridget K Buckmeier Butz; Sean C Jameson; Ajay Kaul; James P Franciosi; Jonathan P Kushner; Philip E Putnam; J Pablo Abonia; Marc E Rothenberg Journal: J Allergy Clin Immunol Date: 2011-01 Impact factor: 10.793
Authors: Chris A Liacouras; Glenn T Furuta; Ikuo Hirano; Dan Atkins; Stephen E Attwood; Peter A Bonis; A Wesley Burks; Mirna Chehade; Margaret H Collins; Evan S Dellon; Ranjan Dohil; Gary W Falk; Nirmala Gonsalves; Sandeep K Gupta; David A Katzka; Alfredo J Lucendo; Jonathan E Markowitz; Richard J Noel; Robert D Odze; Philip E Putnam; Joel E Richter; Yvonne Romero; Eduardo Ruchelli; Hugh A Sampson; Alain Schoepfer; Nicholas J Shaheen; Scott H Sicherer; Stuart Spechler; Jonathan M Spergel; Alex Straumann; Barry K Wershil; Marc E Rothenberg; Seema S Aceves Journal: J Allergy Clin Immunol Date: 2011-04-07 Impact factor: 10.793
Authors: Glenn T Furuta; Chris A Liacouras; Margaret H Collins; Sandeep K Gupta; Chris Justinich; Phil E Putnam; Peter Bonis; Eric Hassall; Alex Straumann; Marc E Rothenberg Journal: Gastroenterology Date: 2007-08-08 Impact factor: 22.682
Authors: Evan S Dellon; Ademola Aderoju; John T Woosley; Robert S Sandler; Nicholas J Shaheen Journal: Am J Gastroenterol Date: 2007-07-07 Impact factor: 10.864
Authors: Marc E Rothenberg; Ting Wen; Allison Greenberg; Oral Alpan; Benjamin Enav; Ikuo Hirano; Kari Nadeau; Sergio Kaiser; Thomas Peters; Antonio Perez; Ieuan Jones; Jonathan P Arm; Robert M Strieter; Ronald Sabo; Kulasiri A Gunawardena Journal: J Allergy Clin Immunol Date: 2014-09-13 Impact factor: 10.793
Authors: Xi Zhang; Edaire Cheng; Xiaofang Huo; Chunhua Yu; Qiuyang Zhang; Thai H Pham; David H Wang; Stuart J Spechler; Rhonda F Souza Journal: PLoS One Date: 2012-11-21 Impact factor: 3.240
Authors: Swathi Eluri; Sara R Selitsky; Irina Perjar; Johnathan Hollyfield; Renee Betancourt; Cara Randall; Spencer Rusin; John T Woosley; Nicholas J Shaheen; Evan S Dellon Journal: Clin Gastroenterol Hepatol Date: 2018-09-10 Impact factor: 11.382
Authors: Brittany T Hines; Matthew A Rank; Benjamin L Wright; Lisa A Marks; John B Hagan; Alex Straumann; Matthew Greenhawt; Evan S Dellon Journal: Ann Allergy Asthma Immunol Date: 2018-05-16 Impact factor: 6.347
Authors: E S Dellon; L L Higgins; R Beitia; S Rusin; J T Woosley; R Veerappan; S R Selitsky; J S Parker; R M Genta; R H Lash; R Aranda; R J Peach; M Grimm Journal: Aliment Pharmacol Ther Date: 2016-05-18 Impact factor: 8.171